Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

BACKGROUND: Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy significantly increased progression-free survival, leading to their approval and incorporation into the metastatic breast cancer treatment paradigm. With these inhibitors being routinely used for patients with advanced estrogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Hitisha K., Tao, Nianjun, Lee, Kyung-Min, Huerta, Mariela, Arlt, Heike, Mullarkey, Tara, Troy, Steven, Arteaga, Carlos L., Bihani, Teeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921513/
https://www.ncbi.nlm.nih.gov/pubmed/31852484
http://dx.doi.org/10.1186/s13058-019-1230-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921513/
https://www.ncbi.nlm.nih.gov/pubmed/31852484
http://dx.doi.org/10.1186/s13058-019-1230-0

Ejemplares similares